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Abstract
Invasive zygomycosis in neonates and children has both similarities to and differences from that in adults. We searched PubMed and
individual references for English-language reports of single cases or case series of neonatal (<1 month) and paediatric (£18 years) zygo-
mycosis and compared the results with published results in adults. Cases were included if they fulﬁlled pre-speciﬁed criteria. A total of
59 cases of neonatal zygomycosis were reported to July 2007; 157 paediatric cases were published up to 2004 and an additional 30
paediatric cases were reported more recently. Prematurity was a major underlying factor among neonatal cases. The most common
manifestations of zygomycosis were gastrointestinal (54%) and cutaneous (36%). This pattern differs from the sinopulmonary and rhino-
cerebral patterns typical in older children and adults. Overall mortality was 64% in neonates, 56% in children and 53% in adults. A ten-
dency for dissemination was higher in neonates than adults. Dissemination and young age (<1 year) were independent risk factors for
death in children. Most patients who survived received antifungal therapy. Surgery combined with antifungal therapy was a protective
factor against death. Most neonates and children who survived had received an amphotericin B formulation. Zygomycosis is a life-threat-
ening infection in children and neonates with differing patterns of involvement in individuals of different ages. The most common man-
agement strategy in survivors involved a combination of amphotericin B and surgery.
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Introduction
Zygomycosis is an invasive fungal infection associated with
very high mortality rates [1]. It refers to a group of uncom-
mon, but frequently fatal, mycoses caused by fungi of the
class Zygomycetes, predominately of the genus Rhizopus.
Zygomycosis has emerged as an increasingly important fungal
infection during the past decade in haematopoietic stem cell
transplant recipients and patients with haematological malig-
nancies. Other adult populations at risk of zygomycosis
include patients with diabetes mellitus, surgical patients,
those with burns or trauma, and patients undergoing defe-
roxamine therapy. In children, zygomycosis may occur in
settings similar to those seen in adults. However, zygomyco-
sis also occurs in certain distinct groups of paediatric
subjects, such as high-risk newborns, patients with type 1
diabetes mellitus, particularly those with uncontrolled
ketoacidosis, and subjects with congenital metabolic aciduria
[1,2]. In the era of broad-spectrum antifungal azoles, an
increase in the numbers of cases of invasive zygomycosis
seen in some centres has coincided with an increase in
voriconazole use in these centres [3]. In this article, we
review published data on invasive zygomycosis in neonates
and older paediatric patients and compare these data with
those from adults.
Zygomycosis in Children
Unlike other ﬁlamentous fungal pathogens that target pre-
dominately immunocompromised hosts, Zygomycetes infect
a broader and more heterogenous population. Recently, we
reviewed the English-language literature for all cases of pae-
diatric zygomycosis published up to 2004 [4]. In this review
[4], we sought to understand the epidemiology, risk factors
and outcomes of zygomycosis in children.
To achieve this, we searched PubMed for English-language
publications of paediatric (0–18 years) zygomycosis cases
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published as single case reports or case series. Individual ref-
erences were reviewed for additional cases. The data were
analysed by logistic regression analysis.
A total of 157 cases (64% male) were identiﬁed in the
review, with a median age of 5 years (interquartile range
(IQR) 0.16, 13); 124 cases referred to patients aged
>1 month [4].
After 2004, when this analysis concluded, a further 30
new cases of zygomycosis in patients aged £18 years were
published in PubMed until August 2008. In a European Con-
federation of Medical Mycology prospective study of zygomy-
cosis in Europe conducted from 2005 to 2007, of a total of
212 zygomycosis patients enrolled, 16 (7.5%) of whom were
paediatric patients (<18 years) [5].
In our analysis, we found that, in addition to previously
recognized risk factors for zygomycosis, such as neutropenia
(18%), malignancy (16%), bone marrow transplantation (6%),
diabetes mellitus (15%) and ketoacidosis (10%), prematurity
was a common co-morbid condition, found in 17% of chil-
dren with zygomycosis. There was also a relatively large
(14%) proportion of patients with no apparent immunocom-
promising condition; however, the assessment of these
patients for defects in innate host defence was highly vari-
able.
The most common patterns of zygomycosis were cutane-
ous (27%), gastrointestinal (21%), rhinocerebral (18%) and
pulmonary (16%). Disseminated infection and young age
(<12 months) were independent risk factors for increased
mortality compared with localized disease and older age,
respectively. This trend may reﬂect the high incidence of
prematurity among paediatric patients, other host differences
that make zygomycosis more fatal in these patients, or other
age-dependent differences, such as difﬁculties in diagnosis or
management or differential reporting of zygomycosis in pae-
diatric and adult patients.
Invasive zygomycosis has not been recognized in patients
with chronic granulomatous disease or other primary im-
munodeﬁciencies as frequently as invasive aspergillosis [6].
Although there is no plausible explanation for this, it may be
that either reporting varies or risks other than phagocytic
impairment are more important for the development of inva-
sive zygomycosis than for aspergillosis.
Zygomycosis in Neonates
Because prematurity is a signiﬁcant risk factor for invasive
zygomycosis among the entire paediatric patient popula-
tion, we conducted a similar but more detailed analysis of
neonates with zygomycosis. We also searched PubMed for
English-language publications of neonatal (0–1 month) zygo-
mycosis cases published up to July 2007 as single case
reports or case series [7]. Individual references were
reviewed for additional cases. A total of 59 cases were
found to have occurred at a median age of 12 days (IQR
8, 18 days). Most of the neonates had been born prema-
turely (73.8%), making prematurity a distinctive underlying
risk factor for the development of zygomycosis, indepen-
dent of the well-known classical risk factors such as diabe-
tes mellitus and haematological malignancies. The patients’
median gestational age was 28 weeks (IQR 25, 39 weeks)
and their median birth weight was 1131 g (IQR 745,
1895 g).
The most common patterns of zygomycosis in neonates
were gastrointestinal (51.0%) and cutaneous (35.6%) disease.
These two patterns of zygomycosis appear to occur more
often in neonates compared with older patients. Mortality is
high, especially for gastrointestinal infection. There are a
number of differences in invasive zygomycosis in neonates
compared with older children and adults (Table 1).
Gastrointestinal zygomycosis is more commonly encoun-
tered in neonates than in paediatric patients and adults (32/
59 (54%) of neonates compared with 17/124 (14%) of pae-
diatric patients aged >1 month and 33/772 (4%) of all
patients aged >18 years) [1,4]. Gastrointestinal disease can
present as necrotizing enterocolitis and is followed by
extremely high mortality (78%). It is often not diagnosed
until immediately before or after the death of the neonate,
which may perhaps occur as a result of the delay in diagno-
sis and the underlying immunodeﬁciency of these babies [8].
Cutaneous disease can either remain localized or extend
through the subdermal tissues, as well as disseminate to
contiguous or remote tissues of the body. Outbreaks of
zygomycosis have been caused by the use of contaminated
TABLE 1. Differences in invasive zygomycosis among neo-
nates, older children and adults
Characteristic
Age
0–1 month
(n = 59)a, n (%)
1 month to 18 years
(n = 124)b, n (%)
>18 years
(n = 772)c, n (%)
Common
risk factors
Prematurity Diabetes,
malignancy
Diabetes, malignancy,
deferoxamine
Mortality 38 (64) 70 (56) 408 (53)
Pattern
Gastrointestinal 32 (54) 17 (14) 33 (4)
Cutaneous 21 (36) 29 (23) 147 (19)
Dissemination 33 (56) 16 (13) 164 (21)
aRoilides et al., unpublished data (2004) [7].
bExtracted from Zaoutis et al. (2007) [4].
cExtracted from Roden et al. (2005) [1].
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wooden tongue depressors or venipunctures through con-
taminated and inﬂamed skin [9,10].
Most of the cases of gastrointestinal disease were
observed in premature babies and some occurred in associa-
tion with progressive necrotizing skin lesions [11], with some
even mimicking the presentation of necrotizing enterocolitis,
but without the pathognomonic sign of pneumatosis intesti-
nalis. Furthermore, although only the small bowel was
involved in cases of necrotizing enterocolitis [12,13], a more
extensive involvement of the gastrointestinal tract, from the
oesophagus to the large bowel, was often observed in pre-
mature neonates with gastrointestinal zygomycosis.
The trend for dissemination to remote organs and indeed
to the whole body, appears to be higher in neonates than in
older children and adults (33/59 (56%) cases in neonates
compared with 16/124 (13%) cases in paediatric patients
aged >1 month and 164/772 (21%) cases in patients aged
>18 years) [1,4]. Thus, early diagnosis and a concerted
attempt to treat neonates with this devastating disease are
very important.
Because the data for systematic reviews on zygomycosis lar-
gely consist of case reports or small series of cases, the results
of these literature analyses may be biased. They do, however,
summarize experience of a rare disease for which no large
studies are expected to be published and should help to
improve understanding of this life-threatening infection.
Diagnostic Approaches and Findings
Diagnostic approaches for invasive zygomycosis in neonates
and children are very limited. There are no ‘typical’ radio-
logical signs; there are no biochemical indices, such as
galactomannan or glucan, and the detection of genetic
material through polymerase chain reaction (PCR) is seldom
available outside reference laboratories. Thus, heightened
suspicion and an effort to obtain a biopsy early in the
course of the disease, or resection of the lesion, is very
important.
Of the paediatric patients identiﬁed in our earlier review
[4], 81 (52%) were diagnosed by histopathology only and 74
(47%) by histology and culture. Among 77 culture-conﬁrmed
cases in paediatric patients, Rhizopus spp. (44%) and Mucor
spp. (15%) were most commonly identiﬁed. Of the neonates,
33 (56%) were diagnosed by histopathology only and 26
(44%) by histopathology and culture [7]. In the 43 patients in
whom an isolate was identiﬁed to genus level, Mucor spp.
was most commonly identiﬁed (18 patients), followed by Rhi-
zopus spp. (15 patients). Among 16 isolates for which species
identiﬁcation was reported, six were identiﬁed as Rhizopus
microsporus, ﬁve as Rhizopus oryzae and ﬁve as Absidia cor-
ymbifera (renamed as Microcladus corymbiferus).
Therapy and Outcome of Invasive
Zygomycosis in Children and Neonates
The mortality of neonates with zygomycosis was 38/59
(64%), compared with 70/124 (56%) in children aged
>1 month to 18 years [4] and 408/772 (53%) in adults aged
>18 years [1]. In a previous analysis of all paediatric cases
published up to 2003, including those concerning neonates,
disseminated infection and young age (<12 months) were
found to be independent risk factors for increased mortality
compared with localized disease and older age, respectively
[4]. This trend may reﬂect the high incidence of prematurity
among paediatric patients, other host differences that make
zygomycosis more likely to be fatal in these patients, or
other age-dependent differences such as difﬁculties in diagno-
sis or management, or differential reporting of zygomycosis
in paediatric and adult patients.
Therapeutic approaches for zygomycosis in neonates and
children are similar to those in adults [14]. Children and
neonates who were diagnosed early and who received anti-
fungal therapy promptly had a mortality rate of 36%, com-
pared with 88% among those who did not receive antifungal
therapy (p <0.0001). Cerebral, gastrointestinal, disseminated
and cutaneous zygomycosis were associated with mortality
rates of 100%, 100%, 88% and 0%, respectively. Independent
risk factors for death were disseminated infection (odds ratio
(OR) 7.18; 95% conﬁdence interval (CI) 3.02–36.59) and age
<1 year (OR 3.85; 95% CI 1.05–7.43).
Of 81 paediatric patients who were given antifungal ther-
apy, 73% received an amphotericin B (AmB) formulation only
[4]. The remaining patients received mostly AmB in combina-
tion with other antifungal agents. Ninety-two (59%) patients
underwent surgery. Among antifungal agents, AmB and par-
ticularly its lipid formulations were mostly administered to
patients who survived.
Surgery appeared to improve the outcome except in the
case of gastrointestinal zygomycosis. The role of surgery in
cases in which it can be applied is deﬁnitive in combination
with antifungal agents. Antifungal therapy, and particularly
surgery, signiﬁcantly improved the outcome of children with
zygomycosis, reducing risk of death by 92% (OR 0.07; 95%
CI 0.04–0.25) and 84% (OR 0.16; 95% CI 0.09–0.61), respec-
tively. Other therapeutic modalities such as hyperbaric oxy-
gen [15], cytokine administration and granulocyte transfusion
in profoundly neutropenic patients are considered as adjunc-
tive therapy without evidence-based clinical effect.
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Amphotericin B continues to represent the mainstay of
medical treatment for invasive zygomycosis in childhood.
Deoxycholate AmB appears to be well tolerated without sig-
niﬁcant nephrotoxicity in most neonates [16,17]. The lipid
formulations of AmB were introduced for clinical care in the
mid-1990s. The optimal dose of liposomal AmB for zygo-
mycosis has not been established, but it is considered to be
>5 mg/kg daily.
Among the newer antifungal agents with activity against
ﬁlamentous fungi (e.g. voriconazole, posaconazole and the
echinocandins), posaconazole, a recently approved, orally
available broad-spectrum triazole, seems to have greater
activity against Zygomycetes [18]. However, the pharmaco-
kinetics and clinical efﬁcacy of posaconazole are largely
unknown in paediatric patients [19]. Two recent studies have
shown overall success rates of 60–70% with posaconazole as
salvage therapy for zygomycosis [20, 21]. Salvage treatment
with posaconazole resulted in successful outcomes in ﬁve of
11 paediatric patients (aged 8–17 years), an effect which
appears similar to that in the adult population [22]. A larger
number of paediatric patients have received the compound
within the manufacturer’s compassionate use programme,
with few differences in safety compared with adult patients
[19]. A paediatric programme has been initiated to deﬁne
doses, safety and tolerance in paediatric patients beyond the
neonatal period. These overall encouraging data suggest that
posaconazole may represent an advance in antifungal therapy
for patients with zygomycosis [20, 22, 23].
Half the neonates identiﬁed did not receive any type of
antifungal treatment. Of the 28 neonates who received anti-
fungal treatment, 27 received an AmB preparation. Mortality
was lower among patients who received an AmB formulation
than among neonates who received no antifungal therapy
(p <0.05). Twenty (33.9%) neonates underwent surgery com-
bined with antifungal treatment. With the exception of two
cutaneous cases, both of whom were cured, all other pat-
terns of zygomycosis carried a mortality rate >80%. From
this detailed analysis, we concluded that zygomycosis is a
very serious infection in neonates, with high mortality, and
that AmB formulations signiﬁcantly improve outcome.
Although neonates with cutaneous and gastrointestinal
zygomycosis were similarly managed with surgical resection,
gastrointestinal infection still carried a worse postoperative
prognosis. By contrast with surgery in cutaneous zygomyco-
sis, surgery did not appear to increase survival among
patients with gastrointestinal zygomycosis. Exploratory lapa-
rotomy and bowel resection were performed in 18 patients,
of whom 11 (61%) died. Despite resection of the infected
bowel, the histopathological diagnosis of zygomycosis was
considerably delayed postoperatively. An increased aware-
ness of this pattern of zygomycosis among neonatologists is
needed to facilitate timely diagnosis and management. In vir-
tually all cases, the preoperative diagnosis was necrotizing
enterocolitis. Gastrointestinal zygomycosis should be consid-
ered as a cause of disease in infants who present with signs
of necrotizing enterocolitis.
Conclusions
The recent study and our earlier review [4, 7] show that zygo-
mycosis is increasingly reported in the literature and must be
considered in ill neonates and children with risk factors for
zygomycosis. Awareness of the likelihood of invasive zygo-
mycosis in high-risk paediatric patients – such as premature
neonates, children with haematological malignancies or diabe-
tes – and early suspicion are the cornerstones for early
diagnosis and potential successful treatment. As in adults, anti-
fungal therapy with AmB combined with resection of the
infected tissues holds the greatest possibility for cure. Posaco-
nazole has activity against Zygomycetes, but it is unclear
whether it can successfully treat invasive zygomycosis and its
pharmacokinetics in infancy and early childhood are unknown.
Neonatal zygomycosis has a high mortality and strong propen-
sity to disseminate; early diagnosis and AmB formulations
combined with surgery may improve an otherwise dismal
outcome.
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